{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:53:41Z","timestamp":1790924021644,"version":"4.1.0"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Toxicol"],"abstract":"<jats:p>Drug-induced seizures are among the most frequent safety concerns for neuroactive drug candidates. Currently, no guidelines are defined for interrogating and mitigating seizure liability. Because of the risks to patient safety during clinical trials, improved nonclinical characterization of seizure liability is an area of intense interest among drug developers and regulators. During the 2022 annual meeting of the American College of Toxicology (ACT), a continuing education course titled \u201cIdentifying and Understanding Seizure Liability in Drug Development\u201d addressed challenges in this field. The course (and now this paper) used a series of detailed nonclinical case studies based on the authors\u2019 experiences to illustrate core principles and a flexible menu of methods to evaluate potential seizure liability. Key points to consider include lists of (1) procedures for detecting seizures and defining their mechanisms when performing pivotal and\/or investigational toxicity studies; (2) constellations of common neurological findings (functional and structural) that indicate potential seizure liability, and in particular (3) event patterns that warrant an electroencephalographic (EEG) study; and (4) major principles for mitigating seizure liability during clinical trials. Taken together, this approach provides a logical workflow by which nonclinical testing of drug-related seizures may be used to best protect patient safety.<\/jats:p>","DOI":"10.1177\/10915818261488768","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:53:12Z","timestamp":1790592792000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Studies in Identifying and Understanding Seizure Liability in Drug Development"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2241-8288","authenticated-orcid":false,"given":"Katie","family":"Sokolowski","sequence":"first","affiliation":[{"name":"Septerna Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Authier","sequence":"additional","affiliation":[{"name":"Charles River Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"McMaster","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration (FDA)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Pressly","sequence":"additional","affiliation":[{"name":"Septerna Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6065-1492","authenticated-orcid":false,"given":"Brad","family":"Bolon","sequence":"additional","affiliation":[{"name":"GEMpath, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus S.","family":"Delatte","sequence":"additional","affiliation":[{"name":"Allucent"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/10915818241307851"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","unstructured":"Gauvin DV Zimmermann ZJ Yoder J Baird TJ. \u201cNot Everything That Shakes Is a Seizure\u201d: Making the Determination of Test Article-Induced Convulsions in Toxicology Studies. Int J Toxicol. 2018 Nov\/Dec;37(6):422-433. doi:10.1177\/1091581818796444. Epub 2018. Sep 24.","DOI":"10.1177\/1091581818796444"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/01926233241300065"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2016.03.002"},{"key":"e_1_3_3_6_2","unstructured":"ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). M3(R2): Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. https:\/\/database.ich.org\/sites\/default\/files\/M3_R2__Guideline.pdf"},{"key":"e_1_3_3_7_2","unstructured":"ICH. S6(R1). Preclinical safety evaluation of biotechnology-derived pharmaceuticals. https:\/\/database.ich.org\/sites\/default\/files\/S6_R1_Guideline_0.pdf"},{"key":"e_1_3_3_8_2","unstructured":"ICH. S9: nonclinical evaluation for anticancer pharmaceuticals. Revised 2009. Last accessed September 9 2026. https:\/\/database.ich.org\/sites\/default\/files\/S9_Guideline.pdf"},{"key":"e_1_3_3_9_2","unstructured":"ICH. S9. Nonclinical evaluation for anticancer pharmaceuticals: questions and answers guidance for industry. Revised 2009. Last accessed September 9 2026. https:\/\/database.ich.org\/sites\/default\/files\/S9_Q%26As_Q%26As.pdf"},{"key":"e_1_3_3_10_2","unstructured":"FDA (U.S. Food and Drug Administration). Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Published 2005. Last accessed September 9 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623319859261"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cotox.2024.100499"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200317140-00002"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.5420"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2019.03.004"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2009.00820.x"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10915818261488768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10915818261488768","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10915818261488768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:16:52Z","timestamp":1790921812000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10915818261488768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":15,"alternative-id":["10.1177\/10915818261488768"],"URL":"https:\/\/doi.org\/10.1177\/10915818261488768","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"10915818261488768"}}